Featured Research

from universities, journals, and other organizations

Nutritional drink for Alzheimer's patients evaluated in clinical trial

Date:
January 29, 2010
Source:
Rush University Medical Center
Summary:
A nationwide clinical trial of a nutritional drink is under way to determine whether it can improve cognitive performance in people with mild to moderate Alzheimer's.

Rush University Medical Center is leading a nationwide clinical trial of a nutritional drink to determine whether it can improve cognitive performance in people with mild to moderate Alzheimer's.

The study follows recently released results from an earlier trial conducted in Europe showing that the drink, called Souvenaid, improved verbal recall in people with mild disease who were followed for three months.

"Our primary goal is to see whether Souvenaid can slow the worsening of memory difficulties in persons with mild to moderate Alzheimer's who are already taking approved treatments for the disease, " said Dr. Raj Shah, medical director of the Rush Memory Clinic and one of the study's lead investigators.

Results of the first European study were released recently following publication in the journal Alzheimer's & Dementia. In that study, 225 patients with mild Alzheimer's were divided into two groups. Some drank Souvenaid and the others sipped a non-medical drink every day for 12 weeks.

Researchers found that the patients who drank Souvenaid improved in a delayed verbal recall task.

A total of 500 individuals who are taking medications approved by the U.S. Food and Drug Administration for the symptomatic treatment of mild to moderate Alzheimer's disease will be enrolled in the present study at 40 sites across the U.S. In the double-blinded study, half of the participants will drink about four ounces of Souvenaid once a day for 24 weeks. The other half will drink a control product that is similar in flavor, appearance, and composition, but without the Souvenaid nutrients. Neither group will know whether they are drinking Souvenaid or the other beverage.

Researchers will test whether the participants' cognitive and functional performance -- including memory, language, attention/concentration, executive functioning, information processing and recall -- shows any greater improvement with Souvenaid than with medication alone.

Rush University Medical Center receives payment from Nutricia for conducting the trial.


Story Source:

The above story is based on materials provided by Rush University Medical Center. Note: Materials may be edited for content and length.


Cite This Page:

Rush University Medical Center. "Nutritional drink for Alzheimer's patients evaluated in clinical trial." ScienceDaily. ScienceDaily, 29 January 2010. <www.sciencedaily.com/releases/2010/01/100125173446.htm>.
Rush University Medical Center. (2010, January 29). Nutritional drink for Alzheimer's patients evaluated in clinical trial. ScienceDaily. Retrieved July 25, 2014 from www.sciencedaily.com/releases/2010/01/100125173446.htm
Rush University Medical Center. "Nutritional drink for Alzheimer's patients evaluated in clinical trial." ScienceDaily. www.sciencedaily.com/releases/2010/01/100125173446.htm (accessed July 25, 2014).

Share This




More Health & Medicine News

Friday, July 25, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Beatings and Addiction: Pakistan Drug 'clinic' Tortures Patients

Beatings and Addiction: Pakistan Drug 'clinic' Tortures Patients

AFP (July 24, 2014) A so-called drugs rehab 'clinic' is closed down in Pakistan after police find scores of ‘patients’ chained up alleging serial abuse. Duration 03:05 Video provided by AFP
Powered by NewsLook.com
Too Few Teens Receiving HPV Vaccination, CDC Says

Too Few Teens Receiving HPV Vaccination, CDC Says

Newsy (July 24, 2014) The Centers for Disease Control and Prevention is blaming doctors for the low number of children being vaccinated for HPV. Video provided by Newsy
Powered by NewsLook.com
New Painkiller Designed To Discourage Abuse: Will It Work?

New Painkiller Designed To Discourage Abuse: Will It Work?

Newsy (July 24, 2014) The FDA approved Targiniq ER on Wednesday, a painkiller designed to keep users from abusing it. Like any new medication, however, it has doubters. Video provided by Newsy
Powered by NewsLook.com
Doctor At Forefront Of Fighting Ebola Outbreak Gets Ebola

Doctor At Forefront Of Fighting Ebola Outbreak Gets Ebola

Newsy (July 24, 2014) Sheik Umar Khan has treated many of the people infected in the Ebola outbreak, and now he's become one of them. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins